SCHEMBL9893829

SCHEMBL9893829

COc1ccc(Cl)cc1-c1c(C(N)=O)nc(-c2cccc(C)c2)n1-c1cc(Cl)ccc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 4/20 0.61
MAPT P10636 5/20 0.43
THRB P10828 1/20 0.43
ALDH1A1 P00352 4/20 0.41
TSHR P16473 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
LMNA P02545 3/20 0.41
TP53 P04637 3/20 0.41
HTT P42858 2/20 0.41
ALOX15 P16050 1/20 0.41
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PDE4D Q08499 1/20 0.40
USP2 O75604 2/20 0.40
MAPK1 P28482 2/20 0.40
CTSA P10619 2/20 0.40
ESR1 P03372 1/20 0.40
HSD17B10 Q99714 3/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893984 0.92 MDM2 (0.50) MDM2MAPTTHRBALDH1A1TSHR
SCHEMBL9894203 0.91 MDM2 (0.73) MDM2MAPTTHRBALDH1A1TSHR
SCHEMBL1437280 0.90 MDM2 (0.48) MDM2MAPTALDH1A1TSHRNPSR1
SCHEMBL9893799 0.90 MDM2 (0.60) MDM2MAPTTHRBALDH1A1TSHR
SCHEMBL9893788 0.89 MDM2 (0.53) MDM2MAPTTHRBALDH1A1TSHR
SCHEMBL1437000 0.86 MDM2 (0.46) MDM2MAPTALDH1A1TSHRNPSR1
SCHEMBL9893677 0.85 MDM2 (0.70) MDM2MAPTALDH1A1MAPK1CTSA
SCHEMBL1437101 0.85 MDM2 (0.82) MDM2MAPTTHRBALDH1A1TP53
SCHEMBL1438284 0.83 MDM2 (0.60) MDM2MAPTTSHRNPSR1LMNA
SCHEMBL9893755 0.83 MDM2 (0.61) MDM2MAPTTHRBALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885MAPT 582/4885THRB 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.